Special Issue

Advanced Research on Molecular Chaperones

Message from the Guest Editor

The intracellular chaperone GRP 78 was first identified as a cell surface signaling receptor in 2001 (reference 301 from CV) This was a surprising observation, but hundreds of subsequent publications have confirmed that cancer cell surface GRP 78 functions as a cell surface receptor regulation pro-proliferative, pro-migratory, and anti-apoptotic signaling cascades. Autoantibodies to the amino-terminal domain of GRP 78 may occur in the plasma of cancer patients. This Special Issue is intended to explore the role of cell surface GRP 78 in transcriptional regulation of cancer cells. This is a promising area of exploration which may lead to improved cancer therapy. We invite potential authors to submit an article to this Special Issue of biomedicines. While GRP 78 has been the best studied chaperone identified on the cell surface, it is not the only member of this group of proteins to occur on the cell surface. For example, HL 60 also occurs on the cell surface of various types of cells. This Special Issue of *Biomedicines* welcomes work involving the role of other chaperones as cell surface proteins which exhibit new functions as regulators of cell function.

Guest Editor

Prof. Dr. Salvatore Vincent Pizzo
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/103249

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).